Escalating dose pretreatment induces pharmacodynamic and not pharmacokinetic tolerance to a subsequent high-dose methamphetamine binge

Synapse

Volumn 60, Issue 6, 2006, Pages 465-473

  O'Neil, Meghan L ^a   Kuczenski, Ronald ^b   Segal, David S ^b   Cho, Arthur K ^a   Lacan, Goran ^a   Melega, William P ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Dopamine; Dopamine transporter; Microdialysis; Striatum

Indexed keywords

3,4 DIHYDROXYPHENYLACETIC ACID; 3BETA (4 FLUOROPHENYL) 2BETA TROPANECARBOXYLIC ACID METHYL ESTER; AMPHETAMINE; DOPAMINE; DOPAMINE TRANSPORTER; HOMOVANILLIC ACID; METHAMPHETAMINE; TRITIUM;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; AUTOPSY; CAUDATE NUCLEUS; CONTROLLED STUDY; CORE TEMPERATURE; CORPUS STRIATUM; DATA ANALYSIS; DIALYSATE; DOPAMINERGIC SYSTEM; DRUG MEGADOSE; DRUG TOLERANCE; GAS CHROMATOGRAPHY; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HISTOPATHOLOGY; MALE; MASS SPECTROMETRY; MICRODIALYSIS; NEUROPROTECTION; NEUROTOXICITY; NONHUMAN; PRIORITY JOURNAL; PUTAMEN; RAT; STEREOTYPY; SUBSTANCE ABUSE;

3,4-DIHYDROXYPHENYLACETIC ACID; AMPHETAMINE; AMPHETAMINE-RELATED DISORDERS; ANIMALS; BODY TEMPERATURE; CENTRAL NERVOUS SYSTEM STIMULANTS; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; COCAINE; DOPAMINE UPTAKE INHIBITORS; GAS CHROMATOGRAPHY-MASS SPECTROMETRY; HOMOVANILLIC ACID; MALE; METHAMPHETAMINE; MICRODIALYSIS; NEOSTRIATUM; RATS; RATS, SPRAGUE-DAWLEY;

EID: 33748588942     PISSN: 08874476     EISSN: 10982396     Source Type: Journal    
DOI: 10.1002/syn.20320     Document Type: Article

References (37)

1. Axt KJ, Commins DL, Vosmer G, Seiden LS. 1990. α-Methyl-p-tyrosine pretreatment partially prevents methamphetamine-induced endogenous neurotoxin formation. Brain Res 515:269-276.
2. Bowyer JF, Tank AW, Newport GD, Slikker W Jr, Ali SF, Holson RR. 1992. The influence of environmental temperature on the transient effects of methamphetamine on dopamine levels and dopamine release in rat striatum. J Pharmacol Exp Ther 260:817-824.
3. Bowyer JF, Gough B, Slikker W Jr, Lipe GW, Newport GD, Holson RR. 1993. Effects of a cold environment or age on methamphetamine-induced dopamine release in the caudate putamen of female rats. Pharmacol Biochem Behav 44:87-98.
4. Brown JM, Hanson GR, Fleckenstein AE. 2000. Methamphetamine rapidly decreases vesicular dopamine uptake. J Neurochem 74: 2221-2223.
5. Davidson C, Gow AJ, Lee TH, Ellinwood EH. 2001. Methamphetamine neurotoxicity. Necrotic and apoptotic mechanisms and relevance to human abuse and treatment. Brain Res Brain Res Rev 36:1-22.
6. Fleckenstein AE, Gibb JW, Hanson GR. 2000. Differential effects of stimulants on monoaminergic transporters: Pharmacological consequences and implications for neurotoxicity. Eur J Pharmacol 406:1-13.
7. Fumagalli F, Gainetdinov RR, Valenzano KJ, Caron MG. 1998. Role of dopamine transporter in methamphetamine-induced neurotoxicity: Evidence from mice lacking the transporter. J Neurosci 18:4861-4869.
8. Gal J. 1977. Synthesis of (R)- and (S)-amphetamine-d3 from the corresponding phenylalanines. J Labelled Cmpd Radiopharm 13:3-9.
9. Gygi MP, Gygi SP, Johnson M, Wilkins DG, Gibb JW, Hanson GR. 1996. Mechanisms for tolerance to methamphetamine effects. Neuropharmacology 35:751-757.
10. Kuczenski R, Segal D. 1989. Concomitant characterization of behavioral and striatal neurotransmitter response to amphetamine using in vivo microdialysis. J Neurosci 9:2051-2065.
11. LaVoie MJ, Hastings TG. 1999. Dopamine quinone formation and protein modification associated with the striatal neurotoxicity of methamphetamine: Evidence against a role for extracellular dopamine. J Neurosci 19:1484-1491.
12. Marek GJ, Vosmer G, Seiden LS. 1990a. Dopamine uptake inhibitors block long-term neurotoxic effects of methamphetamine upon dopaminergic neurons. Brain Res 513:274-279.
13. Marek GJ, Vosmer G, Seiden LS. 1990b. The effects of monoamine uptake inhibitors and methamphetamine on neostriatal 6-hydroxydopamine (6-OHDA) formation, short-term monoamine depletions and locomotor activity in the rat. Brain Res 516:1-7.
14. McCann UD, Wong DF, Yokoi F, Villemagne V, Dannals RF, Ricaurte GA. 1998. Reduced striatal dopamine transporter density in abstinent methamphetamine and methcathinone users: Evidence from positron emission tomography studies with [11C]WIN-35,428. J Neurosci 18:8417-8422.
15. Melega WP, Williams AE, Schmitz DA, DiStefano EW, Cho AK. 1995. Pharmacokinetic and pharmacodynamic analysis of the actions of D-amphetamine and D-methamphetamine on the dopamine terminal. J Pharmacol Exp Ther 274:90-96.
16. Melega WP, Raleigh MJ, Stout DB, Lacan G, Huang SC, Phelps ME. 1997. Recovery of striatal dopamine function after acute amphetamine- and methamphetamine-induced neurotoxicity in the vervet monkey. Brain Res 766:113-120.
17. Melikian HE, Buckley KM. 1999. Membrane trafficking regulates the activity of the human dopamine transporter. J Neurosci 19: 7699-7710.
18. Perez-Reyes M, White WR, McDonald SA, Hicks RE, Jeffcoat AR, Hill JM, Cook CE. 1991. Clinical effects of daily methamphetamine administration. Clin Neuropharmacol 14:352-358.
19. Riddle EL, Kokoshka JM, Wilkins DG, Hanson GR, Fleckenstein AE. 2002. Tolerance to the neurotoxic effects of methamphetamine in young rats. Eur J Pharmacol 435:181-185.
20. Robinson TE, Whishaw IQ. 1988. Normalization of extracellular dopamine in striatum following recovery from a partial unilateral 6-OHDA lesion of the substantia nigra: A microdialysis study in freely moving rats. Brain Res 450:209-224.
21. Sandoval V, Riddle EL, Ugarte YV, Hanson GR, Fleckenstein AE. 2001. Methamphetamine-induced rapid and reversible changes in dopamine transporter function: An in vitro model. J Neurosci 21:1413-1419.
22. Saunders C, Ferrer JV, Shi L, Chen J, Merrill G, Lamb ME, Leeb-Lundberg LM, Carvelli L, Javitch JA, Galli A. 2000. Amphetamine-induced loss of human dopamine transporter activity: an internalization-dependent and cocaine-sensitive mechanism. Proc Natl Acad Sci USA 97:6850-6855.
23. Schmidt CJ, Ritter JK, Sonsalla PK, Hanson GR, Gibb JW. 1985. Role of dopamine in the neurotoxic effects of methamphetamine. J Pharmacol Exp Ther 233:539-544.
24. Segal DS, Kuczenski R. 1974. Tyrosine hydroxylase activity: Regional and subcellular distribution in the brain. Brain Res 68:261-266.
25. Segal DS, Kuczenski R. 1997a. An escalating dose "binge" model of amphetamine psychosis: Behavioral and neurochemical characteristics. J Neurosci 17:2551-2566.
26. Segal DS, Kuczenski R. 1997b. Repeated binge exposures to amphetamine and methamphetamine: Behavioral and neurochemical characterization. J Pharmacol Exp Ther 282:561-573.
27. Segal DS, Kuczenski R. 1999. Escalating dose-binge stimulant exposure: Relationship between emergent behavioral profile and differential caudate-putamen and nucleus accumbens dopamine responses. Psychopharmacology (Berl) 142:182-192.
28. Segal DS, Kuczenski R, O'Neil ML, Melega WP, Cho AK. 2003. Escalating dose methamphetamine pretreatment alters the behavioral and neurochemical profiles associated with exposure to a high-dose methamphetamine binge. Neuropsychopharmacology 28:1730-1740.
29. Seiden LS, Commins DL, Vosmer G, Axt K, Marek G. 1988. Neurotoxicity in dopamine and 5-hydroxytryptamine terminal fields: A regional analysis in nigrostriatal and mesolimbic projections. Ann N Y Acad Sci 537:161-172.
30. Sekine Y, Iyo M, Ouchi Y, Matsunaga T, Tsukada H, Okada H, Yoshikawa E, Futatsubashi M, Takei N, Mori N. 2001. Methamphetamine-related psychiatric symptoms and reduced brain dopamine transporters studied with PET. Am J Psychiatry 158:1206-1214.
31. Tong J, Ross BM, Schmunk GA, Peretti FJ, Kalasinsky KS, Furukawa Y, Ang LC, Aiken SS, Wickham DJ, Kish SJ. 2003. Decreased striatal dopamine D1 receptor-stimulated adenylyl cyclase activity in human methamphetamine users. Am J Psychiatry 160:896-903.
32. Vaughan RA, Huff RA, Uhl GR, Kuhar MJ. 1997. Protein kinase C-mediated phosphorylation and functional regulation of dopamine transporters in striatal synaptosomes. J Biol Chem 272:15541-15546.
33. Volkow ND, Chang L, Wang GJ, Fowler JS, Franceschi D, Sedler M, Gatley SJ, Miller E, Hitzemann R, Ding YS, Logan J. 2001. Loss of dopamine transporters in methamphetamine abusers recovers with protracted abstinence. J Neurosci 21:9414-9418.
34. Wang GJ, Volkow ND, Chang L, Miller E, Sedler M, Hitzemann R, Zhu W, Logan J, Ma Y, Fowler JS. 2004. Partial recovery of brain metabolism in methamphetamine abusers after protracted abstinence. Am J Psychiatry 161:242-248.
35. Wilson JM, Kalasinsky KS, Levey AI, Bergeron C, Reiber G, Anthony RM, Schmunk GA, Shannak K, Haycock JW, Kish SJ. 1996. Striatal dopamine nerve terminal markers in human, chronic methamphetamine users. Nat Med 2:699-703.
36. Xie T, McCann UD, Kim S, Yuan J, Ricaurte GA. 2000. Effect of temperature on dopamine transporter function and intracellular accumulation of methamphetamine: Implications for methamphetamine-induced dopaminergic neurotoxicity. J Neurosci 20:7838-7845.
37. Zhu SJ, Kavanaugh MP, Sonders MS, Amara SG, Zahniser NR. 1997. Activation of protein kinase C inhibits uptake, currents and binding associated with the human dopamine transporter expressed in Xenopus oocytes. J Pharmacol Exp Ther 282:1358-1365.